Juan Carlos Q Velez1, Ndidiamaka O Obadan2, Amit Kaushal3, Mohammed Alzubaidi2, Bhavna Bhasin4, Sachin H Sachdev5, Nithin Karakala6, John M Arthur6, Ross M Nesbit7, Gautam M Phadke3. 1. Department of Nephrology, Ochsner Foundation Hospital, Ochsner Health System, New Orleans, Louisiana, USA. 2. Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. 3. Department of Internal Medicine and Nephrology, University of North Dakota School of Medicine, Sanford Health Medical Center, Fargo, North Dakota, USA. 4. Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 5. Department of Nephrology, Ochsner Health System, Covington, Louisiana, USA. 6. Division of Nephrology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 7. Division of Nephrology, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, USA.
Abstract
BACKGROUND: Vancomycin-associated (VA) acute kidney injury (AKI) is being increasingly recognized. A distinct pattern of rapid rise in serum creatinine (sCr) during VA-AKI has occasionally been observed. However, such scenarios remain underreported. METHODS: We conducted an online survey at the American Society of Nephrology Communities forum and reviewed publications of VA-AKI via PubMed or Google searching for cases of precipitous AKI (those with rise in sCr ≥1.5 mg/dL/day) attributable to vancomycin. RESULTS: We identified 12 original cases compiled from 6 different hospitals and 4 published cases (n = 16; 38% women, age 43.5 ± 16 years, weight 108 ± 23 kg, body mass index 35 ± 7 kg/m2) of precipitous AKI observed shortly after large cumulative doses of VA (8.8 ± 5 g). The median steepest 24-h rise in sCr was 2.6 mg/dL (range 1.5-3.5 mg/dL) and the slope of the initial 48-h sCr rise was greater than that of a control AKI (non-VA, n = 48) group (2.03 ± 0.1 vs. 0.62 ± 0.0 mg/dL/day; p < 0.0001). The steep rise in sCr in the VA-AKI was not accompanied by anuria. Overt rhabdomyolysis was absent in all cases. Further, in 3 precipitous VA-AKI cases, simultaneous serum cystatin C values did not rise precipitously, suggesting that the reductions in glomerular filtration rate were overestimated by the sCr increase. CONCLUSIONS: VA-AKI can manifest with a precipitous rise in sCr shortly after a high cumulative dose of vancomycin. True toxic tubular injury overrepresented by the sCr rise is postulated.
BACKGROUND:Vancomycin-associated (VA) acute kidney injury (AKI) is being increasingly recognized. A distinct pattern of rapid rise in serum creatinine (sCr) during VA-AKI has occasionally been observed. However, such scenarios remain underreported. METHODS: We conducted an online survey at the American Society of Nephrology Communities forum and reviewed publications of VA-AKI via PubMed or Google searching for cases of precipitous AKI (those with rise in sCr ≥1.5 mg/dL/day) attributable to vancomycin. RESULTS: We identified 12 original cases compiled from 6 different hospitals and 4 published cases (n = 16; 38% women, age 43.5 ± 16 years, weight 108 ± 23 kg, body mass index 35 ± 7 kg/m2) of precipitous AKI observed shortly after large cumulative doses of VA (8.8 ± 5 g). The median steepest 24-h rise in sCr was 2.6 mg/dL (range 1.5-3.5 mg/dL) and the slope of the initial 48-h sCr rise was greater than that of a control AKI (non-VA, n = 48) group (2.03 ± 0.1 vs. 0.62 ± 0.0 mg/dL/day; p < 0.0001). The steep rise in sCr in the VA-AKI was not accompanied by anuria. Overt rhabdomyolysis was absent in all cases. Further, in 3 precipitous VA-AKI cases, simultaneous serum cystatin C values did not rise precipitously, suggesting that the reductions in glomerular filtration rate were overestimated by the sCr increase. CONCLUSIONS:VA-AKI can manifest with a precipitous rise in sCr shortly after a high cumulative dose of vancomycin. True toxic tubular injury overrepresented by the sCr rise is postulated.
Authors: Nuala J Meyer; Michael G S Shashaty; Todd A Miano; Sean Hennessy; Wei Yang; Thomas G Dunn; Ariel R Weisman; Oluwatosin Oniyide; Roseline S Agyekum; Alexandra P Turner; Caroline A G Ittner; Brian J Anderson; F Perry Wilson; Raymond Townsend; John P Reilly; Heather M Giannini; Christopher V Cosgriff; Tiffanie K Jones Journal: Intensive Care Med Date: 2022-07-14 Impact factor: 41.787